

SPECIFICATION AMENDMENTS

The paragraph beginning at p. 10, line 30 of the specification has been amended as follows.

D¹ In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:1, as shown in Figures 1A-D. Ankrd2V is 329 ~~330~~ amino acids in length. Pfam analysis indicates that there are four ankyrin domains from F149 ~~151~~ to R181 ~~183~~, from L182 ~~184~~ to K214 ~~216~~, from L215 ~~217~~ to R247 ~~249~~, and from E248 ~~250~~ to L280 ~~282~~. Useful antigenic epitopes extend from about F136 ~~137~~ to L154 ~~155~~ and from about N279 ~~280~~ to L288 ~~289~~; an oligopeptide useful for distinguishing between Ankrd2V and a related homolog extends from about G293 ~~30~~ to K34; and a biologically active portion of Ankrd2V extends from about L182 ~~184~~ to K214 ~~216~~. An antibody which specifically binds Ankrd2V is useful in an assay to identify a clear cell sarcoma or to distinguish between clear cell sarcoma and other muscle cancers.

The paragraph beginning at p. 11, line 20 has been amended as follows.

These preferred variants have from about 82% to about 91% identity as shown in the table below. The first column shows the SEQ ID for the human cDNA; the second column, the SEQ IDvar for variant cDNAs; the third column, the clone number for the variant cDNAs; the fourth column, the percent identity to the human cDNA; and the fifth column, the alignment of the variant cDNA to the human cDNA.

D²

SEQ ID _H	SEQ ID _{var}	Clone _{var}	Identity	Nt _H Alignment
<u>23</u>	7	700911986	82%	14-263
<u>23</u>	8	701144158	91%	188-273
<u>23</u>	9	700188047	86%	379-630
<u>23</u>	10	700913268	87%	743-930

These cDNAs are particularly useful for producing transgenic cell lines or organisms which model human disorders and upon which potential therapeutic treatments for such disorders may be tested.